Back to Archived Journals » Orphan Drugs: Research and Reviews » Volume 2

Wilson’s disease: a review of treatment options with a focus on zinc therapy

Authors Hui J, Tang

Received 15 May 2012

Accepted for publication 9 August 2012

Published 11 October 2012 Volume 2012:2 Pages 35—45

DOI https://doi.org/10.2147/ODRR.S33896

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


J Hui,1 NL Tang2

1Department of Pediatrics, 2Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Abstract: Wilson’s disease, an inherited disorder of copper metabolism, is well known for its remarkable heterogeneous clinical presentation and variable organ involvement. Since its first introduction almost five decades ago, zinc – with its relative lack of side effects and safety profile – has gained a lot of attention and favor over other therapeutic agents for the treatment of Wilson’s disease. Traditional chelating agents like D-penicillamine and trientine, although proven to be efficacious, compared less favorably to zinc because of their long list of potential side effects. The medical literature regarding the use of zinc generally supports its primary role in the treatment of presymptomatic/asymptomatic, pediatric, and pregnant patients. However, for symptomatic patients – especially the symptomatic hepatic patients, long-term follow-up studies concluded that zinc is less effective than chelating agents in preventing hepatic deterioration. Other treatment concepts like combination therapy using zinc in conjunction with a chelating agent or sequential treatment with initial chelating agents followed by zinc have been tried with variable success. Rigorously designed studies and safety data on these newer treatment concepts are not yet available. Independent of the chosen medical regimen, nonadherence or discontinuation with noncompliance is the biggest threat adversely affecting the long-term outcome in all treated patients with Wilson’s disease. Close monitoring as well as long-term follow-up for the development of new neurologic or hepatic symptoms are essential for all patients, irrespective of how long they have been on treatment and whether treatment has remained static for years. In this paper, the authors will discuss the current opinion and role of zinc in the treatment of various manifestations and different stages of Wilson’s disease.

Keywords: Wilson’s disease, treatment, zinc

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]